On the other hand, the company said, “This award is grossly disproportionate with the initial compensatory award in this case, and the Company is confident it will be overturned.”
“This award for a single plaintiff stands in stark contrast with the initial $680,000 compensatory award and is a clear violation of due process. United States Supreme Court precedent dictates that punitive damages awards that are a double-digit multiplier of the compensatory award should be set aside,” added Johnson & Johnson.
Furthermore, the company emphasized that the court excluded key evidence, which prevented it to defend itself meaningfully. As a result, the jury did not hear that its label for Risperdal appropriately and clearly outlined the benefits and risks associated with the antipsychotic drug.
